For instance, BRAF/MEK inhibitors can mitigate the immunosuppressive milieu often associated with advanced melanoma, facilitating increased T cell infiltration and enhancing anti-tumor responses triggered by ICIs (173, 194). The gene discussed is MAP2K7; the disease is melanoma.